You are here :
Polycythemia Vera Pipeline Review H1 2018
Published on: Feb 2018 | From USD $2000 | Published By: GMD | Number Of Pages: 84
Polycythemia Vera - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.
Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 3 and 2 respectively.
Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets DirectŐs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology).
- The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and itŐs most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycythemia Vera - Overview
Polycythemia Vera - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Polycythemia Vera - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycythemia Vera - Companies Involved in Therapeutics Development
AbbVie Inc
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Italfarmaco SpA
Nerviano Medical Sciences Srl
PharmaEssentia Corp
SELLAS Life Sciences Group Inc
Polycythemia Vera - Drug Profiles
anagrelide hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idasanutlin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycythemia Vera - Dormant Projects
Polycythemia Vera - Discontinued Products
Polycythemia Vera - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials
Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting
Dec 10, 2017: PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017
Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
Nov 27, 2017: Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting
Jun 25, 2017: AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
Mar 14, 2017: AOP Orphan Pharmaceuticals announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera
Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016
Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation
Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012
May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition
Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Polycythemia Vera, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Polycythemia Vera - Pipeline by AbbVie Inc, H1 2018
Polycythemia Vera - Pipeline by Bristol-Myers Squibb Co, H1 2018
Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Polycythemia Vera - Pipeline by Gilead Sciences Inc, H1 2018
Polycythemia Vera - Pipeline by Italfarmaco SpA, H1 2018
Polycythemia Vera - Pipeline by Nerviano Medical Sciences Srl, H1 2018
Polycythemia Vera - Pipeline by PharmaEssentia Corp, H1 2018
Polycythemia Vera - Pipeline by SELLAS Life Sciences Group Inc, H1 2018
Polycythemia Vera - Dormant Projects, H1 2018
Polycythemia Vera - Discontinued Products, H1 2018 List of Figures
Number of Products under Development for Polycythemia Vera, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
FAQs
The process usually includes collection and interpretation of market data by using statistical and analytical techniques to support the decision making process.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Market research reports provide in-depth analysis about the market conditions and requirements for effective decision making.
The report provides a snapshot of the global market size, segmentation data, marketing growth strategies, market share, export and import information, analysis and forecast of market trends, competition, domestic production, best sales prospects, statistical data, tariffs, regulations, distribution and business practices, end-user analysis, contact points and more.
These research reports include information about competitive strategies, solutions, fact-based research, key takeaways, recommendations, market considerations, emerging business models and market opportunities for multiple segments of an industry.
Market research reports assist in solving business problems and making better decisions to improve business as per the prevalent market trends.
Any person who has the capacity to make decisions for the business must buy the reports. These reports help management in decision making process. Market research helps person to obtain market information from different sources, and in multiple formats. It aims to study supply and demand, analyze data as per geography, age factors, demography, technology, product, psychographic & gender differences, and many other parameters. Access to in-depth market trends helps person to assess the market effectiveness. Some of the multiple techniques used for market research include customer analysis, choice modeling, competition and risk analysis, product research, advertising the research, marketing mix modeling, simulated test marketing, and more.
Market research studies several features of business environment, such as competitors, market structure, government regulations, economic trends, technological advances and financial analysis of companies, industries, and sectors. This helps person in the decision-making process of planning and implementing strategies for their markets.
1. Choose a topic.
2. Make skeleton catalogue.
3. Fill content. As for report content, there are two main information source, Primary and Secondary data collection. Secondary data collectionrefers to information searched from the Internet or data bought from database. Primary data collection refers to information concluded from telephone interview, face-to-face interview, expert’s interview, meeting etc.
4. Audit the report
5. Publish the report.
With regard to information cost, information searching costs the least, database support the second least, and telephone interview the third least. Face-face interview cost higher, in-depth interview much higher and expert interview the highest. A research may adopt all of these approaches, or just some of them.
In general, a good-quality research report needs 1-3 months to be finished. Time and method varies according to different Publishers. Thus, it’s difficult to define an exact procedure or process of making research report. Both time and cost vary. However, specialization has become a basic industry standard. Professional and dedicated products will be more and more popular.
There may be exceptions to this if you place order on a non-working day specifically because our publisher partners are located all over the globe. In case of physical delivery report will be couriered to you within 3 working days from the date of the receipt of payment and delivery time will differ based on your location
Why Us
In-depth database
Our Report’s database covers almost all topics of all regions over the Globe..
Recognised publishing sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales support.
Safe & Secure
Complete secure payment process.